-+ 0.00%
-+ 0.00%
-+ 0.00%

HLB to Absorb HLB Life Science in Share-Swap Merger

PUBT·11/19/2026 09:10:18
HLB to Absorb HLB Life Science in Share-Swap Merger
  • HLB will absorb HLB Life Science in a stock-based merger scheduled to take effect July 1, 2027.
  • HLB Life Science shareholders will receive 0.0857532 shares in the surviving company for each share held.
  • The transaction will involve issuing 8,674,057 common shares, equivalent to 6.51% of the surviving company's current outstanding shares.
  • The merger aims to consolidate rights and revenue streams for cancer drug rivoceranib while simplifying the group structure.
  • Completion remains subject to HLB Life Science shareholder approval and competition clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLB Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261119000398), on November 19, 2026, and is solely responsible for the information contained therein.